Optimal duration of adjuvant tamoxifen treatment in elderly breast cancer patients: Influence of age, comorbidities, and various effectiveness hypotheses on life-expectancy and cost

Breast Disease

Volumn 9, Issue 6, 1996, Pages 327-339

  Extermann, Martine ^a   Balducci, Lodovico ^a   Lyman, Gary H ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Aged; Aged > 80; Breast neoplasms; Comorbidity; Tamoxifen

Indexed keywords

TAMOXIFEN;

AGE; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; FEMALE; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; TIME;

EID: 0029801144     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;339:1-15.
2. Fisher, B. Brown A, Wolmark N. et al.: Prolonging tamoxifen therapy for primary breast cancer. Ann Intern Med 1987;106:649-654.
3. McDonald CC, Stewart HJ: Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. Br J Med 1991;303:435-437.
4. Rutqvist LE, Mattson A: Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 1993;85:1398-1406.
5. Love RR, Mazess RB, Barden HS, et al.: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-856.
6. Kristensen B, Eljertsen B, Dalgaard P, et al.: Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study. J Clin Oncol 1994;12:992-997.
7. Jordan VC: Overview from the international conference on long-term tamoxifen therapy for breast cancer. J Natl Cancer Inst 1992;84:231-234.
8. Howell A, Dodwell DJ, Anderson H, Redford J: Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol 1992;3:611-617.
9. Centers for Disease Control and Prevention. Vital statistics of the United States, 1990. Volume II, section 6, table 6-3.
10. Beck J, Kassirer JP, Pauker SG: A convenient approximation of life expectancy (the "DEALE"). Am J Med 1982;73:883-897.
11. Castiglione M, Gelber R, Goldhirsch A: Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality. J Clin Oncol 1990;8:519-526.
12. Murabito JM, Evans JC, Larson MG, Levy D: Prognosis after the onset of coronary heart disease. Circulation 1993;88:2548-2555.
13. Mouridsen HT, Rose C, Overgaard M, et al.: Adjuvant treatment of postmenopausal patients with high risk primary breast cancer. Acta Oncol 1988;27:699-705.
14. Cummings FJ, Gray R, Tormey DC, et al.: Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long-term follow-up and causes of death. J Clin Oncol 1993;11:29-35.
15. Fisher B, Costantino J, Redmond C, et al.: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479-484.
16. Saphner T, Tormey DC, Gray R: Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991;9:286-294.
17. Hull RD, Raskob GE, Pineo GF, et al.: Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992;326:975-982.
18. Prandoni P, Lensing AWA, Buller HR, et al.: Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441-445.
19. Fornander T, Rutqvist LE, Cedermark B, et al.: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989;i:117-119.
20. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerman L, Cronin WM: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-537.
21. van Leeuwen FE, Benraadt J, Coebergh JWW, et al.: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-452.
22. Jordan VC, Morrow M: Should clinicians be concerned about the carcinogenic potential of tamoxifen? Eur J Cancer 1994;11:1714-1721.
23. Furr BJA, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharm Ther 1984;25:127-205.
24. Ludwig Breast Cancer Study Group: Randomised trial of chemo-endocrine therapy, endocrine therapy, and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastasis. Lancet 1984;i:1256-1260.
25. Breast Cancer Trials Committee, Scottish Cancer Trials Office: Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Lancet 1987;ii:171-175.
26. Christman K, Muss HB, Case D, Stanley V: Chemotherapy of metastatic breast cancer in the elderly. JAMA 1992;268:57-62.
27. Clark GM, Sledge GW, Osborne K, McGuire W: Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 1987;5:55-61.
28. Buzdar AU: Chemotherapeutic approaches to advanced breast cancer. Semin Oncol 1988;15:65-70.
29. Leivonen MK, Kalima TV: Prognostic factors associated with survival after breast cancer recurrence. Acta Oncol 1991;30:583-586.
30. Fornander T, Rutqvist LE, Glas U: Response to tamoxifen and fluoxymesterone in a group of breast cancer patients with disease recurrence after cessation of adjuvant tamoxifen. Cancer Treat Rep 1987;71:685-688.
31. Goldhirsch A, Gelber RD, Price KN, et al.: Effect of systemic adjuvant treatment on first sites of breast cancer relapse. Lancet 1994;343:377-381.
32. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ: Probabilistic sensitivity analysis using Monte Carlo simulation. Med Decis Making 1985;5:157-177.
33. Hillner BE, Smith TJ: Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. N Engl J Med 1991;324:160-168.
34. Mandelblatt JS, Wheat ME, Monane M, Moshief RD, Hollenberg JP, Tang J: Breast cancer screening for elderly women with and without comorbid conditions. Ann Intern Med 1992;116:722-730.
35. Satariano WA, Ragland DR: The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994;120:104-110.
36. Limits on tamoxifen duration questioned. Oncology News Internat 1996;5:1-8.
37. Adjuvant therapy of breast cancer-tamoxifen update. Clinical Announcement. National Cancer Institute, November 30, 1995.
38. Early Breast Cancer Trialists' Cooperative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. N Engl J Med 1988;319:1681-1692.